Boston Scientific Invests $1.5 Billion in MiRus for Next-Generation TAVR: Deal Structure, the SIEGEL Valve, and the Structural Heart Market

The Deal at a Glance

On May 18, 2026, Boston Scientific Corporation (NYSE: BSX) and MiRus LLC announced a landmark strategic investment under which Boston Scientific will acquire approximately 34% of MiRus as a non-voting equity stake for $1.5 billion in cash. Simultaneously, Boston Scientific secured an exclusive option to acquire the SIEGEL transcatheter aortic valve replacement (TAVR) system business for additional cash payments totaling $3 billion, subject to clinical and regulatory milestones -- bringing the total potential transaction value to $4.5 billion.

The deal also grants Boston Scientific an exclusive option to acquire MiRus's mitral and tricuspid replacement valve assets for an additional payment, and provides for sales-based payments to MiRus tied to net sales of the SIEGEL valve over a specified period. The transaction is expected to be immaterial to Boston Scientific's adjusted earnings per share in 2026.

Notably, Boston Scientific announced a separate $2 billion accelerated share repurchase (ASR) agreement on the same day, signaling financial confidence and a strategy that balances external growth investments with shareholder returns.

Who Are the Players

Boston Scientific: Filling the TAVR Void

Boston Scientific is one of the world's largest medical device companies, with a diversified portfolio spanning interventional cardiology, peripheral interventions, electrophysiology, endoscopy, urology, and neuromodulation. The Marlborough, Massachusetts-based company generated approximately $20.1 billion in revenue in 2025 and has been one of the most active acquirers in medtech.

The MiRus investment addresses a critical gap in Boston Scientific's structural heart portfolio. The company has a long and troubled history with TAVR:

• LOTUS Edge: Boston Scientific acquired the LOTUS TAVR system through its $435 million acquisition of Symetis in 2017 and developed the next-generation LOTUS Edge valve. The program was retired in November 2020 due to "complexities" with the product's mechanical leaflet release mechanism and concerns about the long-term commercial viability of the platform.
• ACURATE Neo2 and ACURATE Prime: These CE-marked, self-expanding TAVR devices were sold commercially outside the United States. In May 2025, Boston Scientific discontinued both products worldwide and ceased pursuing U.S. regulatory approval, effectively exiting the TAVR market entirely.

For nearly a year, Boston Scientific has been without any TAVR product in its portfolio -- a conspicuous absence in one of the fastest-growing segments of interventional cardiology. The MiRus deal changes that decisively.

The MiRus investment also follows Boston Scientific's $14.5 billion acquisition of Penumbra, Inc. announced earlier in 2026, making this a year of bold, transformative moves for the company under CEO Mike Mahoney.

Lance Bates, Executive Vice President and President of Interventional Cardiology at Boston Scientific, stated: "The occurrence and recognition of aortic stenosis is growing rapidly and our investment in MiRus continues our pursuit to bring a differentiated TAVR system into our portfolio, providing a new treatment option for patients with severe aortic stenosis."

MiRus LLC: A Biomaterials Innovator from Georgia

MiRus LLC is a privately held medical device company based in Marietta, Georgia, in the Atlanta metropolitan area. The company was founded to develop and commercialize proprietary biomaterials, implants, and procedural solutions for both cardiovascular and orthopedic diseases.

MiRus's core technology platform centers on proprietary rhenium-based alloys -- advanced metallic biomaterials that offer a combination of mechanical strength, biocompatibility, and radiological properties that surpass conventional medical device metals such as cobalt-chromium, titanium, and nickel-titanium (Nitinol). The company has applied this materials science platform across multiple therapeutic areas, with the SIEGEL TAVR system being its most advanced cardiovascular application.

The company's founder and CEO is Jay Yadav, MD, a physician-entrepreneur with a track record of innovation in interventional cardiology. Dr. Yadav is a serial medtech founder; he previously founded CardioMEMS (acquired by St. Jude Medical, now Abbott, for $345 million in 2014), which developed the FDA-approved CardioMEMS Heart Failure System -- the first and only FDA-approved wireless heart failure monitoring device.

Dr. Yadav commented on the transaction: "The SIEGEL valve is a promising technology and has received enthusiastic feedback from physician investigators for its less invasive delivery, nickel-free construct, precise placement resulting from a lack of foreshortening and excellent hemodynamics. We are excited to partner with Boston Scientific, a leader in interventional cardiology, to advance the SIEGEL valve through its pivotal clinical trial and toward commercialization."

The SIEGEL TAVR Valve: A Technology Deep Dive

The SIEGEL transcatheter aortic valve represents a fundamentally different engineering approach to TAVR -- one that addresses several long-standing limitations of currently available devices. Every major design decision in the SIEGEL valve appears to have been made in response to specific clinical pain points associated with existing Edwards Lifesciences and Medtronic TAVR platforms.

Nickel-Free, Balloon-Expandable Design

The SIEGEL valve is the first nickel-free, balloon-expandable TAVR valve. This is a meaningful differentiator. All currently available balloon-expandable TAVR valves use a nickel-titanium (Nitinol) frame, and self-expanding valves from Medtronic and others use Nitinol as well. Approximately 20% of the U.S. population has some degree of nickel sensitivity or allergy. In most patients, the nickel in TAVR frames is contained within the body and does not cause clinically significant issues, but nickel hypersensitivity remains a concern -- particularly for patients with known metal allergies, where exposure can trigger inflammatory responses, eczematous reactions, or potentially accelerate valve deterioration.

By eliminating nickel entirely from the frame material, the SIEGEL valve addresses this population directly and may also reduce chronic inflammatory responses at the tissue-implant interface in all patients, regardless of allergy status.

Rhenium Alloy Frame

The SIEGEL valve's frame is constructed from a proprietary molybdenum-rhenium (Mo-Re) alloy -- a material with origins partly inspired by NASA research into high-performance metals for extreme environments. This is MiRus's core intellectual property and the technology platform that differentiates the company across its entire product portfolio.

Rhenium-based alloys offer several properties that make them uniquely suited for structural heart applications:

• Superior radial strength: The Mo-Re alloy exhibits radial strength greater than both cobalt-chromium and titanium alloys, allowing for a thinner, lower-profile frame that still provides sufficient radial force to anchor securely within the calcified aortic annulus.
• Excellent fatigue resistance: Structural heart implants must withstand hundreds of millions of cardiac cycles over a patient's lifetime. Rhenium alloys demonstrate exceptional fatigue performance under cyclic loading conditions.
• Biocompatibility: Molybdenum-rhenium alloys have demonstrated favorable biocompatibility profiles in preclinical testing, with reduced inflammatory response compared to nickel-containing alloys.
• Radiopacity: The high atomic number of rhenium provides excellent fluoroscopic visibility, aiding physicians during valve deployment -- a practical advantage in the catheterization lab.

The frame is coated with a proprietary nitric oxide (NO) coating, which is designed to promote endothelialization (healing and tissue integration) and reduce thrombogenicity (blood clot formation) at the blood-contacting surfaces of the valve frame.

Open Cell Frame Design and Zero Foreshortening

The SIEGEL valve employs an open cell frame design that eliminates foreshortening -- the tendency of a compressed valve frame to shorten as it expands during deployment. In current TAVR systems, foreshortening makes precise placement challenging because the valve's final position shifts as it expands. This unpredictability can lead to:

• Malposition requiring repositioning or a second valve
• Paravalvular leak (PVL) due to incomplete sealing against the annulus
• Coronary ostia obstruction if the valve is placed too high
• Conduction system injury and pacemaker requirement if the valve sits too deep

The SIEGEL valve's zero-foreshortening design means the valve deploys exactly where the physician positions it. This provides intrinsic commissural alignment (the structural posts of the valve align naturally with the patient's native coronary anatomy), more predictable sealing, and reduced risk of conduction disturbances. The elimination of foreshortening alone could be a meaningful clinical advantage, as pacemaker implantation rates after TAVR remain a significant concern -- ranging from approximately 8% to over 30% depending on the valve platform and patient anatomy.

Dry Porcine Tissue Leaflets

The SIEGEL valve uses porcine (pig) pericardial tissue leaflets treated with an anti-calcification process and stored in a dry state. This contrasts with the glutaraldehyde-fixed, liquid-stored leaflets used in most current surgical and transcatheter tissue valves.

Dry tissue processing offers several potential advantages:

• Shelf stability: Elimination of liquid storage simplifies inventory management and eliminates concerns about glutaraldehyde degradation over time.
• Reduced calcification risk: Anti-calcification treatments applied to dry-processed tissue may reduce the rate of structural valve degeneration, potentially extending the functional life of the valve.
• Improved tissue handling properties: Dry tissue may offer superior crimpability and re-expansion characteristics compared to wet-stored tissue, contributing to the valve's low-profile delivery.

8 French Delivery System

Perhaps the most striking engineering achievement of the SIEGEL platform is its delivery system. The SIEGEL valve is delivered through an 8 French (approximately 2.67 mm inner diameter) expandable delivery sheath for all valve sizes -- 23mm, 26mm, and 29mm.

This is approximately 50% smaller than current TAVR delivery sheaths. For comparison, the Edwards eSheath+ used with the Edwards SAPIEN 3 Ultra platform typically requires 14-16 French access, and Medtronic's Evolut platforms use 14-18 French delivery systems depending on valve size.

The clinical implications of an 8 French delivery system are substantial:

• Reduced vascular complications: The most common procedural complication in TAVR is vascular injury at the femoral access site, including dissection, perforation, and hematoma. Smaller sheath diameter directly correlates with lower vascular complication rates.
• Broader patient access: Many patients -- particularly women, who tend to have smaller iliofemoral vessels -- are excluded from transfemoral TAVR or face higher complication rates due to vessel size limitations. An 8 French system could enable transfemoral access in nearly all patients regardless of vessel anatomy.
• Simpler access technique: 8 French access may not require surgical cutdown or advanced closure devices in many patients, potentially reducing procedure time, cost, and complexity.
• Elimination of alternative access routes: Patients who currently require transapical, transaortic, or transcarotid access due to unfavorable iliofemoral anatomy may become candidates for standard transfemoral approach.

Dr. Vinod H. Thourani, MD, Director of Structural Heart and Valve Center at Piedmont Heart Institute in Atlanta and a leading TAVR investigator, stated: "8 French system with such precise placement and low gradients and no PVL is not a combination I ever expected in THV. A THV without nickel is also much needed."

Valve Pre-Mounted on Balloon

The SIEGEL valve is pre-mounted directly onto the delivery balloon at the factory. Current TAVR systems typically require the valve to be crimped onto the balloon in the catheterization laboratory, adding procedural steps, time, and the potential for crimping-related valve damage or asymmetric deployment. Pre-mounting streamlines procedure setup and may contribute to more consistent, predictable valve expansion.

Summary of SIEGEL Technical Specifications

The STAR Pivotal Clinical Trial

Trial Design

The FDA granted Investigational Device Exemption (IDE) approval for the STAR (Siegel Transcatheter Aortic Valve Replacement) pivotal trial -- the definitive clinical study designed to support a Premarket Approval (PMA) application for the SIEGEL valve in the United States.

The STAR trial will enroll up to 1,025 patients with severe symptomatic aortic stenosis across all surgical risk categories (low, intermediate, high, and prohibitive) at clinical sites throughout the United States. The all-risk-category design is consistent with current TAVR clinical practice and reflects the evolution of the field since the earliest TAVR trials, which were restricted to prohibitive-risk patients only.

Clinical Timeline

The clinical development of the SIEGEL valve has progressed through several milestones:

• First-in-human (FIH) implantation: Data from the initial FIH experience was presented at the New York Valves conference in 2024, generating significant interest from the interventional cardiology community.
• Early feasibility study (EFS) 30-day results: Positive 30-day outcomes from the early feasibility study were presented at New York Valves 2025, demonstrating encouraging hemodynamic performance, low paravalvular leak rates, and favorable safety outcomes.
• STAR pivotal trial: Currently enrolling or preparing to enroll at U.S. sites, with IDE approval granted by FDA.

It is important to note that the SIEGEL valve is an investigational device. It is not approved for commercial distribution or clinical use in any country. The STAR trial will generate the pivotal data required to support FDA review and, if successful, eventual commercial approval.

Regulatory Pathway: PMA for a Class III Device

TAVR valves are Class III medical devices regulated under the FDA's Premarket Approval (PMA) pathway -- the most stringent device approval pathway. The PMA process requires demonstration of reasonable assurance of safety and effectiveness through robust clinical evidence, typically from a randomized controlled trial or a well-designed single-arm study with an objective performance goal.

For the SIEGEL valve, the regulatory strategy likely involves:

• IDE approval (already granted) -- permission to conduct the clinical investigation
• STAR pivotal trial enrollment and follow-up -- generating the primary safety and effectiveness endpoint data
• PMA submission -- compiling clinical data, engineering test results, manufacturing information, and labeling into a comprehensive application
• FDA review and panel meeting -- the FDA may convene an Advisory Panel meeting to review the data
• PMA approval -- if the FDA determines the device is safe and effective

Given the size of the STAR trial (1,025 patients) and the need for follow-up data, the timeline to PMA approval is likely several years, with commercial availability in the United States dependent on successful trial completion and FDA review.

Deal Structure: Strategic Optionality with Milestone-Linked Risk

The Boston Scientific-MiRus transaction is structured as a multi-layered deal with significant optionality -- a structure that reflects both the early-stage regulatory status of the SIEGEL valve and the magnitude of the potential opportunity.

Layer 1: Equity Investment ($1.5 Billion)

Boston Scientific's initial $1.5 billion investment secures an approximately 34% non-voting equity stake in MiRus LLC. This structure provides Boston Scientific with:

• Economic exposure to MiRus's entire business, including both the cardiovascular franchise (SIEGEL TAVR, mitral, tricuspid valves) and the orthopedic/spine business
• Information rights and board observation (expected, though not publicly confirmed), giving Boston Scientific visibility into MiRus's operations, clinical progress, and strategic decisions
• No voting control, which preserves MiRus's operational independence during the clinical development phase

The non-voting structure is significant. Boston Scientific is not acquiring control of MiRus -- it is making a strategic bet on the company's technology platform while allowing MiRus to continue operating independently. This structure avoids the integration complexity of a full acquisition while securing preferential access to the SIEGEL valve.

Layer 2: Exclusive Option to Acquire SIEGEL TAVR Business ($3 Billion)

Boston Scientific holds an exclusive option to acquire the SIEGEL TAVR system business for additional cash payments totaling $3 billion. These payments are subject to the achievement of clinical and regulatory milestones -- meaning Boston Scientific only pays the full amount if the SIEGEL valve successfully completes clinical trials and receives regulatory approval.

This milestone-linked structure de-risks the investment for Boston Scientific. If the STAR trial fails to meet its primary endpoints, or if the FDA does not approve the device, Boston Scientific's exposure is limited to the $1.5 billion equity investment. The company is not obligated to exercise the acquisition option.

Layer 3: Mitral and Tricuspid Valve Option

The deal also grants Boston Scientific an exclusive option to acquire MiRus's mitral and tricuspid replacement valve assets. These represent earlier-stage programs that extend the strategic value of the partnership beyond aortic valve replacement into the broader structural heart space, where transcatheter mitral and tricuspid interventions represent large, under-penetrated markets.

Layer 4: Sales-Based Payments

MiRus is eligible for additional payments based on net sales of the SIEGEL valve over a specified period, providing ongoing economic participation in the commercial success of the product.

Risk Allocation Summary

This structure is characteristic of how large strategics invest in clinical-stage medical device companies: provide substantial upfront capital to fund development, secure exclusive commercial rights through options, and tie the largest payments to de-risking milestones. Boston Scientific is effectively paying $1.5 billion for the privilege of potentially paying $3 billion more if the technology works -- a structure that signals strong conviction in the SIEGEL platform while maintaining financial discipline.

Boston Scientific's TAVR Journey: Third Time's the Charm?

A History of TAVR Setbacks

Boston Scientific's path to a viable TAVR portfolio has been marked by two major program failures:

LOTUS Edge (Retired November 2020): The LOTUS platform was a mechanically deployable, self-expanding TAVR valve with a unique adaptive seal designed to minimize paravalvular leak. Boston Scientific acquired the technology through its $435 million acquisition of Symetis SA in 2017. The next-generation LOTUS Edge received CE mark in Europe but was voluntarily retired before receiving FDA approval. The company cited "complexities" related to the product's mechanical leaflet release mechanism, which led to reported issues with valve leaflet immobilization and challenges in manufacturing consistency. The retirement resulted in a pre-tax charge of approximately $225 million.

ACURATE Neo2 / ACURATE Prime (Discontinued May 2025): These self-expanding TAVR systems were also part of the Symetis acquisition. The ACURATE platform had a long clinical history in Europe but never achieved FDA approval in the United States. Boston Scientific discontinued both products in May 2025, ending all TAVR sales worldwide and ceasing pursuit of U.S. approval. The decision reflected the commercial reality: without a U.S. presence in the world's largest TAVR market, the economics of maintaining a global TAVR franchise were unfavorable.

Why the MiRus Deal Is Different

Several factors suggest that the SIEGEL valve may succeed where LOTUS Edge and ACURATE failed:

• Balloon-expandable design: The SIEGEL valve is balloon-expandable, aligning it with the dominant deployment mechanism favored by most TAVR operators (the Edwards SAPIEN platform is balloon-expandable). Both prior BSX TAVR programs were self-expanding.
• Simpler mechanism: The SIEGEL valve does not rely on complex mechanical release mechanisms (which doomed LOTUS Edge) or elaborate delivery systems. The balloon-expandable design with pre-mounted valve is inherently simpler.
• Smaller delivery profile: The 8 French delivery system is a genuine differentiator that no competing platform can currently match. This gives the SIEGEL valve a clear commercial advantage in patient populations with small vessel anatomy.
• Nickel-free differentiation: The nickel-free construct addresses a real, underserved clinical need and provides a clear marketing narrative.
• Founded by a physician with a track record: Jay Yadav, MD, successfully navigated CardioMEMS through FDA approval and a $345 million exit. His experience in regulatory strategy and clinical trial execution is directly relevant to the SIEGEL program.

Competitive Landscape: The TAVR Market

Current Market Leaders

The global TAVR market is dominated by two players, with a third making significant investments:

Edwards Lifesciences (Dominant): Edwards pioneered TAVR with the SAPIEN platform and remains the global market leader. The SAPIEN 3 Ultra and SAPIEN 3 Ultra RESILIA valves are the most widely used balloon-expandable TAVR devices in the world. Edwards generated approximately $6.1 billion in total revenue in 2025, with the majority derived from TAVR. The company also recently introduced the SAPIEN X4 system in Europe and is pursuing FDA approval. Edwards's strengths include a massive body of clinical evidence, deep physician relationships, and an extensive commercial infrastructure.

Medtronic (Challenger): Medtronic's Evolut R, Evolut PRO, and Evolut PRO+ platforms are the leading self-expanding TAVR systems. The Evolut platform has gained market share through its supra-annular valve design (which can provide superior hemodynamics in certain anatomies) and its expanding sizes. Medtronic has invested heavily in clinical trials demonstrating non-inferiority and, in some analyses, superiority to surgical valve replacement across risk categories.

Abbott (Emerging): Abbott's Navitor TAVR system is a self-expanding valve with an active cuff designed to minimize paravalvular leak. Abbott entered the TAVR market through its acquisition of Tendyne Holdings and has been building its clinical evidence base. Abbott's existing structural heart strength in mitral (MitraClip) and tricuspid (TriClip) interventions gives it a platform advantage.

JenaValve (Early Stage): JenaValve Technology is developing a purpose-built transcatheter valve for aortic regurgitation (in addition to aortic stenosis) and has received FDA Breakthrough Device Designation for its JenaValve Pericardial TAVR System for pure aortic regurgitation.

Where SIEGEL Fits

The SIEGEL valve would enter a competitive market but with several points of differentiation that could capture meaningful market share:

1. The 8 French advantage: No other commercially available TAVR system offers an 8 French delivery profile. If the clinical data supports the promise, this alone could drive adoption among operators treating patients with small vessel anatomy.
2. Nickel-free: A genuine differentiator for the 20% of Americans with nickel sensitivity, and potentially appealing to all patients and physicians as a cleaner materials profile.
3. Zero foreshortening: Simplifies deployment and may reduce pacemaker rates -- a persistent concern with all TAVR platforms.
4. Boston Scientific commercial muscle: BSX has a massive interventional cardiology sales force and deep hospital relationships. If the SIEGEL valve receives FDA approval, Boston Scientific's commercial infrastructure could drive rapid uptake.

The Structural Heart Growth Thesis

The broader structural heart market is one of the most attractive growth areas in medical devices, driven by aging populations, expanding clinical indications, and improving procedural outcomes:

• Aortic stenosis prevalence is growing in both occurrence and recognition as screening programs expand and physician awareness increases. The estimated addressable patient population continues to grow as TAVR indications expand to lower surgical risk categories.
• TAVR procedure volumes have grown from approximately 5,000 procedures globally in 2010 to over 200,000 annually, with continued double-digit growth projected.
• Transcatheter mitral and tricuspid interventions represent the next wave of structural heart growth, with large, under-treated patient populations and multiple devices in clinical development.

Boston Scientific's investment in MiRus is not just about a single TAVR valve -- it is about establishing a position in the structural heart market that could eventually span aortic, mitral, and tricuspid interventions, all built on a proprietary biomaterials platform.

Implications for the Medical Device Industry

For Competitors

Edwards Lifesciences and Medtronic should take note. Boston Scientific's re-entry into TAVR -- with a genuinely differentiated technology platform -- introduces a formidable third competitor into what has been effectively a duopoly. The 8 French delivery system, if validated in the STAR trial, could force competitors to invest in their own low-profile delivery systems, potentially accelerating innovation across the entire TAVR market.

For MiRus and the Rhenium Platform

The deal validates MiRus's rhenium alloy technology platform as a materials science breakthrough with significant commercial value. If the SIEGEL valve succeeds, the underlying rhenium alloy technology could be applied across a wide range of cardiovascular and orthopedic implants, potentially creating a new class of metallic biomaterials for medical devices.

For Investors and Analysts

The transaction structure -- equity investment plus milestone-linked acquisition option -- is a model that other strategics may replicate for clinical-stage medical device companies. It allows large acquirers to secure access to innovative technology while limiting downside exposure if clinical development fails. The total potential deal value of $4.5 billion also establishes a significant valuation benchmark for privately held structural heart companies.

For RA/QA Professionals

The SIEGEL valve's regulatory pathway (IDE, pivotal trial, PMA) serves as a case study in the FDA's approach to next-generation TAVR devices. Key regulatory considerations include:

• PMA supplement vs. de novo PMA: As a new device with novel materials (rhenium alloy) and a novel delivery mechanism (8 French), the SIEGEL valve requires a full PMA rather than a supplement to an existing approval.
• Materials characterization: Extensive testing of the molybdenum-rhenium alloy frame will be required, including fatigue testing, corrosion resistance, biocompatibility (ISO 10993), and long-term durability data.
• Clinical trial design: The STAR trial's all-risk-category design reflects current TAVR clinical practice and FDA expectations for new TAVR devices.
• Combination product considerations: The nitric oxide coating on the frame may raise combination product questions, potentially involving both CDRH and CDER in the regulatory review.

What Comes Next

The road from announcement to commercial product is long, particularly for a Class III medical device requiring PMA approval. Key milestones to watch:

1. STAR pivotal trial enrollment initiation: The commencement and pace of enrollment will be closely watched as an indicator of physician enthusiasm and site commitment.
2. 30-day and 1-year STAR data: Interim analyses from the pivotal trial will provide the first large-scale clinical evidence for the SIEGEL valve.
3. PMA submission timing: Depends on trial enrollment speed and data collection timelines, but is likely several years out.
4. Regulatory milestones: Achievement of the clinical and regulatory milestones that trigger Boston Scientific's $3 billion acquisition option payments.
5. Exercise of acquisition option: Boston Scientific's decision on whether and when to exercise its option to acquire the SIEGEL TAVR business will signal the company's conviction in the technology based on emerging clinical data.
6. Mitral and tricuspid programs: Updates on MiRus's mitral and tricuspid valve programs, which represent additional optionality for Boston Scientific.

In the meantime, Boston Scientific's $1.5 billion investment buys the company a seat at the structural heart table, access to a potentially disruptive technology platform, and the optionality to build a comprehensive TAVR, mitral, and tricuspid franchise -- or walk away if the data does not support it.

For a company that has twice failed to establish a TAVR presence, the MiRus deal represents a carefully structured, third attempt with a differentiated technology and a partnership model that limits downside while preserving upside. Whether the SIEGEL valve delivers on its promise will be one of the most closely watched stories in structural heart over the coming years.

Disclosure: This analysis is for informational purposes only and does not constitute investment advice. The author has no financial position in any of the companies mentioned. The SIEGEL valve is an investigational device not approved for commercial distribution in any country.